Navigation Links
Medivation Announces Third Quarter 2010 Financial Results Teleconference and Webcast on November 5, 2010
Date:10/29/2010

SAN FRANCISCO, Oct. 29 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss third quarter 2010 financial results and provide a general business update on November 5, 2010, at 4:30 p.m. Eastern Time. A press release for the third quarter ended September 30, 2010 will be released after markets close on November 5, 2010.

Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Pfizer and Astellas, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Medivation Announces Second Quarter 2010 Financial Results Teleconference and Webcast on August 9, 2010
2. Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
3. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
4. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
5. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
6. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
7. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
8. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
9. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
11. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... N.J. , April 19, 2017  Novartis ... by the National Heart, Lung, and Blood Institute ... demonstrating that 58% of patients with treatment-naïve severe ... months when treated with eltrombopag at the initiation ... . The study evaluated three sequential treatment groups, ...
(Date:4/18/2017)... April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and providing ... is in conjunction with this morning,s announcement of the ... and Nutritional Insufficiency businesses. Cardinal Health now ... will be at the bottom of its previous guidance ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... The National ... upon National Registry of Emergency Medical Technicians and welcomes this organization ... Dr. Jan G. West, Ph.D. , CEO & Organizational Psychologist at NBRI. ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... improve the profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers more effectively ... dairy proteins, providing direct cost savings as well as more stable pricing over ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... signed an agreement to be the preferred physical therapy provider for Derby City ... them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s sports ...
(Date:4/25/2017)... ... ... The doctors at Wall Centre Dental are now expanding their practice by ... to receive dental care. The doctors offer three treatment options to put victims of ... surgery, at their dental office in Vancouver. Wall Centre Dental is currently welcoming even ...
(Date:4/25/2017)... ... 25, 2017 , ... Back Pain Centers of America (BPC), which ... physician in their area, announces the launch of a new and proprietary customer relationship ... looking for reputable physicians to help them with back or neck pain and helps ...
Breaking Medicine News(10 mins):